All three generations of EGFR‐TKIs serve as standard first‐line treatments for NSCLC patients with EGFR‐sensitive mutations, primarily comprising exon 19 deletions (19del) and the L858R point mutation in exon 21 (21L858R) [1, 2, 3, 4]. Here, EGFR is linked to non-small cell lung carcinoma.